Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-Adapted Therapy for Young Children With Brain Tumors
NCT00602667Phase 2Active, not recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Dec 2007
- Primary completion
- Sep 2017
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, open-label trial of methotrexate in central nervous system tumor, medulloblastoma, primitive neuroectodermal tumor (PNET) and 5 more (3 arms), sponsored by St. Jude Children's Research Hospital. Primary endpoints: Progression-free Survival at 1 year, Progression-free Survival by DNA Methylation Subgroup at 1 year and 1 more. Started Dec 2007; status: active, not recruiting.
02
Drugs
methotrexate
03
Conditions
central nervous system tumormedulloblastomaprimitive neuroectodermal tumor (PNET)pineoblastoma (PB)Atypical teratoid rhabdoid tumor (ATRT)
Beyond the preview
Go deeper on NCT00602667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00602667.